Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 May 1;38(3):201–207. doi: 10.1007/BF01525642

Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction

David W Hoskin 1,✉, Teresa Reynolds 1, Jonathan Blay 2
PMCID: PMC11038949  PMID: 8124689

Abstract

Adoptive immunotherapy with lymphokine-activated killer (LAK) cells has shown some promise in the treatment of certain cancers that are unresponsive to conventional treatment approaches. However, colon adenocarcinomas tend to respond poorly to LAK therapy, possibly as a result of tumor-induced immunosupprression. Recently, in vivo administration of anti-CD3 antibody has been shown to induce mouse T lymphocytes to mediate major-histocompatibility-complex(MHC)-unrestricted tumoricidal activity which is distinet from natural-killer-cell-derived LAK activity. It has therfore been suggested that anti-CD3 therapy may find application in tumor immunotherapy in humans. However, the effectiveness of anti-CD3-activated killer cell induction within the environment found in the vicinity of colon adenocarcinoma cells has not been evaluated. The present report demonstrates that colon cancer cells of human (HT-29) and mouse (MCA-38) origin markedly inhibit the generation of activated killer cells in murine spleen cell cultures. DNA synthesis and interleukin-2 production by spleen cells following stimulation with anti-CD3 antibody are also profoundly depressed in the presence of MCA-38 and HT-29 adenocarcinoma cells. MCA-38- and HT-29-mediated inhibition of activated killer cell development is exerted through the production of a tumor-associated soluble factor that is distinct from transforming growth factor β or prostaglandins. Local immunosupression associated with sites of tumor growth may therefore represent a major obstacle to successful anti-CD3 immunotherapy of certain colon adenocarcinomas.

Key words: Colon cancer, Immune supression, Anti-CD3-antibody, MHC-unrestricted CTL

References

  • 1.Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, Grieg R. Growth factor production by human colon carcinoma cell lines. Cancer Res. 1989;49:2898. [PubMed] [Google Scholar]
  • 2.Belldegrun A, Kasid A, Uppenkamp M, Topalian S, Rosenberg SA. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA and relevance to cancer immunotherapy. J Immunol. 1989;142:4520. doi: 10.4049/jimmunol.142.12.4520. [DOI] [PubMed] [Google Scholar]
  • 3.Callewaert DM, Kaplan J, Peterson WD. Suppression of lymphocyte activation by a factor produced byMycoplasma arginini. Immunol. 1975;115:1662. [PubMed] [Google Scholar]
  • 4.Cummings K, Robertson R. Prostaglandin: increased production by renal cell carcinoma. J Urol. 1977;118:720. doi: 10.1016/S0022-5347(17)58172-0. [DOI] [PubMed] [Google Scholar]
  • 5.Dohi Y, Sunada S, Aoki M, Moriguchi A, Okabayashi M, Miyata M, Matsuda H. Eadication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody. Cancer Immunol Immunother. 1993;36:357. doi: 10.1007/BF01742251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dohlsten M, Sundstedt A, Bjorklund M, Hedlund G, Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer. 1993;54:482. doi: 10.1002/ijc.2910540321. [DOI] [PubMed] [Google Scholar]
  • 7.Ebert EC, Roberts AI, Devereux D, Nagase H. Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res. 1990;50:6158. [PubMed] [Google Scholar]
  • 8.Ellenhorn JDI, Hirsch R, Schreiber H, Bluestone A. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988;242:569. doi: 10.1126/science.2902689. [DOI] [PubMed] [Google Scholar]
  • 9.Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel L-H, Grau G, Bluestone J, Bach J-F, Chatenoud L. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 1990;20:509. doi: 10.1002/eji.1830200308. [DOI] [PubMed] [Google Scholar]
  • 10.Gallinger S, Hoskin DW, Mullen JBM, Wong AHC, Roder IC. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-I experimental hepatic metastasis in C57BL/6 mice. Cancer Res. 1990;50:2476. [PubMed] [Google Scholar]
  • 11.Grimm EA, Muzumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomena. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hoskin DW, Stankova J, Anderson SK, Roder JC. Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibody. Cancer Immunol Immunother. 1989;29:226. doi: 10.1007/BF00200000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huang SS, O'Grady P, Huang JS. Hunman transforming growth factor β, α2-macroglobulin complex is a latent form of transforming growth factor β. J Biol Chem. 1988;263:1535. doi: 10.1016/S0021-9258(19)57337-9. [DOI] [PubMed] [Google Scholar]
  • 14.Jin B, Scott JL, Vadas MA, Burns GF. TGF-β down regulates TL: SA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology. 1989;66:570. [PMC free article] [PubMed] [Google Scholar]
  • 15.June CH, Fletcher MC, Ledbetter JA, Schiever GL, Siegel JN, Phillips AF, Samelson LE. Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci USA. 1990;87:7722. doi: 10.1073/pnas.87.19.7722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kupper MC, Hamou M, Bodmer S, Fontana A, de Tribolet N. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer. 1988;42:562. doi: 10.1002/ijc.2910420416. [DOI] [PubMed] [Google Scholar]
  • 17.Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl Acad Sci USA. 1987;84:1374. doi: 10.1073/pnas.84.5.1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Loeffler CM, Symth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, Tase JE, Urba WJ, Leonard AS, Young HA, Ochoa AC. Immunoregulation in cancer-bearing hosts. Downregulation of gene expression and cytotoxic function in CD8+T cells. J Immunol. 1992;149:949. doi: 10.4049/jimmunol.149.3.949. [DOI] [PubMed] [Google Scholar]
  • 19.Maraskovsky E, Chen W-F, Shortman K. IL-2 and IFN-γ are two necessary lynphokines in the development of cytolytic T cells. J Immunol. 1989;143:1210. doi: 10.4049/jimmunol.143.4.1210. [DOI] [PubMed] [Google Scholar]
  • 20.Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486. doi: 10.1200/JCO.1989.7.4.486. [DOI] [PubMed] [Google Scholar]
  • 21.Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992;258:1795. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  • 22.Mule JJ, Schwartz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor beta inhibits the in vitro generation of lymphokine-activated killeer cells and cytotoxic T cells. Cancer Immunol Immunother. 1988;26:95. doi: 10.1007/BF00205600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nelson DS, Nelson M. Evasion of host defenses by tumors. Immunol Cell Biol. 1987;65:287. doi: 10.1038/icb.1987.33. [DOI] [PubMed] [Google Scholar]
  • 24.Phillips JH, Lanier LL. Disection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pillay DJ, Karmazyn M, Pope BL. Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: modulatory role of prostaglandins. Int J Immunopharmacol. 1986;8:227. doi: 10.1016/0192-0561(86)90063-9. [DOI] [PubMed] [Google Scholar]
  • 26.Rice SQJ, Crane IJ, Scully C, Prime SS. Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cells lines. Scand J Immunol. 1992;36:443. doi: 10.1111/j.1365-3083.1992.tb02959.x. [DOI] [PubMed] [Google Scholar]
  • 27.Roberts AB, Sporn MB. Transforming growth factor beta. Adv Cancer Res. 1988;51:107. doi: 10.1016/S0065-230X(08)60221-3. [DOI] [PubMed] [Google Scholar]
  • 28.Salmon SE, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, editor. Basic and clinical pharmacology. 5th edn. Norwalk: Appleton and Lange; 1992. pp. 766–800. [Google Scholar]
  • 29.Stankova J, Hoskin DW, Roder JC. Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations. Cell Immunol. 1989;121:13. doi: 10.1016/0008-8749(89)90002-6. [DOI] [PubMed] [Google Scholar]
  • 30.Tsang M, Weatherbee JA, Dietz M, Kitamura T, Lucas RC. TGF-beta specifically inhibits the IL-4-dependent proliferation of multifactor-dependent murine T helper and human hematopoietic cell lines. Lymphokine Res. 1990;9:607. [Google Scholar]
  • 31.Watson GA, Fu Y-X, Lopez DM. Splenic macrophages from tumor-hearing mice co-experissing. Mac-1 and Mac-2 antigens exert immunoregulatory funtions via two distinet mechanisms. J Leukoc Biol. 1991;49:126. doi: 10.1002/jlb.49.2.126. [DOI] [PubMed] [Google Scholar]
  • 32.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES